Ebenezer A. Kio

1.8k total citations
29 papers, 711 citations indexed

About

Ebenezer A. Kio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Ebenezer A. Kio has authored 29 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Ebenezer A. Kio's work include Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and PARP inhibition in cancer therapy (7 papers). Ebenezer A. Kio is often cited by papers focused on Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and PARP inhibition in cancer therapy (7 papers). Ebenezer A. Kio collaborates with scholars based in United States, Russia and Canada. Ebenezer A. Kio's co-authors include Adedayo A. Onitilo, Suhail A.R. Doi, Tapas K. Sengupta, Yoko Otake, Robert K. Stuart, Sridharan Soundararajan, James C. Smith, Daniel Fernandes, Mauricio Pineda‐Roman and Eleanor K. Spicer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ebenezer A. Kio

27 papers receiving 701 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ebenezer A. Kio United States 10 350 269 255 85 83 29 711
Kwai Han Yoo South Korea 15 270 0.8× 210 0.8× 183 0.7× 48 0.6× 90 1.1× 50 588
Nagla Abdel Karim United States 13 286 0.8× 184 0.7× 194 0.8× 48 0.6× 45 0.5× 61 634
Chie-Schin Shih United States 10 553 1.6× 259 1.0× 326 1.3× 54 0.6× 63 0.8× 11 847
Pablo Gajate Spain 15 329 0.9× 102 0.4× 146 0.6× 59 0.7× 72 0.9× 51 601
Tahir Latif United States 13 214 0.6× 108 0.4× 211 0.8× 50 0.6× 91 1.1× 38 588
Alejandro Avilés‐Salas Mexico 14 369 1.1× 249 0.9× 295 1.2× 81 1.0× 40 0.5× 62 768
Florentia Dimitriou Switzerland 16 665 1.9× 150 0.6× 250 1.0× 230 2.7× 87 1.0× 50 936
Antonio Cusmai Italy 11 292 0.8× 124 0.5× 197 0.8× 138 1.6× 24 0.3× 28 577
Gil Awada Belgium 15 450 1.3× 151 0.6× 176 0.7× 156 1.8× 132 1.6× 58 691

Countries citing papers authored by Ebenezer A. Kio

Since Specialization
Citations

This map shows the geographic impact of Ebenezer A. Kio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ebenezer A. Kio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ebenezer A. Kio more than expected).

Fields of papers citing papers by Ebenezer A. Kio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ebenezer A. Kio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ebenezer A. Kio. The network helps show where Ebenezer A. Kio may publish in the future.

Co-authorship network of co-authors of Ebenezer A. Kio

This figure shows the co-authorship network connecting the top 25 collaborators of Ebenezer A. Kio. A scholar is included among the top collaborators of Ebenezer A. Kio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ebenezer A. Kio. Ebenezer A. Kio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clarke, Jeffrey, Jyoti D. Patel, Francisco Robert, et al.. (2021). Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. Lung Cancer. 161. 180–188. 21 indexed citations
2.
Danilov, Alexey V., Charles Herbaux, Harriet S. Walter, et al.. (2020). Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(12). 2810–2818. 47 indexed citations
3.
4.
Durm, Greg Andrew, Sandra K. Althouse, Salma K. Jabbour, et al.. (2019). P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Journal of Thoracic Oncology. 14(10). S627–S627. 1 indexed citations
5.
Henry, Leonard R., et al.. (2019). PD01.17 Successful Implementation of a Free Lung Cancer Screening Program in a Rural Tertiary Care Hospital Setting. Journal of Thoracic Oncology. 14(11). S1139–S1140.
6.
Durm, Greg Andrew, Sandra K. Althouse, Alia Sadiq, et al.. (2018). OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 13(10). S321–S321. 6 indexed citations
7.
8.
Durm, Greg Andrew, Sandra K. Althouse, Ahad A. Sadiq, et al.. (2018). Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.. Journal of Clinical Oncology. 36(15_suppl). 8500–8500. 43 indexed citations
9.
Clarke, Jeffrey, Jyoti D. Patel, Francisco Robert, et al.. (2018). Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.. Journal of Clinical Oncology. 36(15_suppl). 3061–3061. 1 indexed citations
10.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations
11.
Chabot, Pierre, Te‐Chun Hsia, Jeong‐Seon Ryu, et al.. (2016). Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology. 131(1). 105–115. 73 indexed citations
12.
13.
Badin, Firas, Anne C. Chiang, William B. Fisher, et al.. (2016). Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.. Journal of Clinical Oncology. 34(15_suppl). e20092–e20092. 2 indexed citations
14.
Witzig, Thomas E., Michael Tomblyn, Jamal Misleh, et al.. (2014). Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 99(11). 1738–1745. 19 indexed citations
15.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2014). A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(5). S4–S5. 3 indexed citations
16.
Starodub, Alexander, Mohammed Milhem, Kenneth Pennington, et al.. (2013). Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.. Journal of Clinical Oncology. 31(15_suppl). e15557–e15557. 2 indexed citations
17.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2013). Anti-CD22 radioimmunotherapy (RIT) combined with anti-CD20 immunotherapy in aggressive non-Hodgkin lymphoma (NHL): Phase I results. 54. 1368–1368. 1 indexed citations
18.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2012). Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results. Blood. 120(21). 3680–3680. 1 indexed citations
19.
Onitilo, Adedayo A., Ebenezer A. Kio, & Suhail A.R. Doi. (2007). Tumor-Related Hyponatremia. Clinical Medicine & Research. 5(4). 228–237. 79 indexed citations
20.
Kio, Ebenezer A., et al.. (2004). Sickle cell crisis associated with hemophagocytic lymphohistiocytosis. American Journal of Hematology. 77(3). 229–232. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kwai Han Yoo Breakdown of academic impact, for papers by Nagla Abdel Karim Breakdown of academic impact, for papers by Chie-Schin Shih Breakdown of academic impact, for papers by Pablo Gajate Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by Alejandro Avilés‐Salas Breakdown of academic impact, for papers by Florentia Dimitriou Breakdown of academic impact, for papers by Antonio Cusmai Breakdown of academic impact, for papers by Gil Awada
Rankless by CCL
2026